Conceptus(R) To Present At Maxim Group Growth Conference

MOUNTAIN VIEW, Calif., Nov. 12, 2010 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure ^® procedure, the most effective non-surgical permanent birth control method available, today announced that Mark Sieczkarek, chief executive officer, is planning to present at the Maxim Group Growth Conference on Thursday, November 18, 2010 at 10:30 a.m. Eastern time at the Grand Hyatt, New York, NY.

A live webcast of the presentation will be available on the company's website at www.conceptus.com . When accessing the webcast through the Conceptus site, select "Investors" then select "Events and Presentations." A replay will be available for a period of 90 days.

About the Essure® Procedure

The Essure procedure, FDA approved since 2002, is the first permanent birth control method that can be performed in the comfort of a physician's office in less than 10 minutes (average hysteroscopic time) without hormones, cutting, burning or the risks associated with general anesthesia or tubal ligation. Soft, flexible inserts are placed in a woman's fallopian tubes through the cervix without incisions. Over the next three months, the body forms a natural barrier around the micro-inserts to prevent sperm from reaching the egg. The Essure procedure is 99.95% effective based on one year of follow up with zero pregnancies reported in clinical trials, making it the most effective form of permanent birth control on the market. The procedure is covered by most insurance plans, and when it is performed in a doctor's office the cost to the patient may be as low as a simple co-pay.

Three months after the Essure procedure, a doctor is able to perform an Essure Confirmation Test to confirm that the inserts are properly placed and the fallopian tubes are fully blocked, giving the patient reliance on Essure for permanent birth control. Essure has been proven and trusted by physicians since 2002, with more than 465,000 women worldwide having undergone the Essure procedure.